Neuropharmacology

2023

Preclinical development of an EP2 antagonist for post-seizure cognitive deficits.

doi:10.1016/j.neuropharm.2022.109356 ·PMID:36460083

Cognitive comorbidities can substantially reduce quality of life in people with epilepsy. Inflammation is a component of all chronic diseases including epilepsy, as well as acute events like status epilepticus (SE). Neuroinflammation is the…

2022

The selective dopamine D1 receptor agonist SKF81297 modulates NMDA receptor currents independently of D1 receptors.

doi:10.1016/j.neuropharm.2022.108967 ·PMID:35077763

Dopamine D1 receptor (D1R) agonists are frequently used to study the role of D1Rs in neurotransmission and behaviour. They have been repeatedly shown to modulate glutamatergic NMDAR currents in the prefrontal cortex (PFC), giving rise to th…

other 2021

Kappa opioid receptor modulation of endometriosis pain in mice

doi:10.1016/j.neuropharm.2021.108677 ·PMID:34153313

The kappa opioid receptor is a constituent of the endogenous opioid analgesia system widely expressed in somatosensory nervous pathways and also in endometrial tissues. This work investigates the possible involvement of kappa opioid recepto…

2020

Valproate reverses stress-induced somatic hyperalgesia and visceral hypersensitivity by up-regulating spinal 5-HT2C receptor expression in female rats.

doi:10.1016/j.neuropharm.2019.107926 ·PMID:31883927

Sodium valproate (VPA) has analgesic effects in clinical and experimental studies, but the mechanisms are still unclear. The present study examined the effects of VPA on stress-induced somatic hyperalgesia and visceral hypersensitivity and …